- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05742204
Plasma proteomiske biomarkører for tidlig diagnose av lungekreft
Identifikasjons- og funksjonell verifiseringsstudie i plasmaproteomiske biomarkører for tidlig diagnose av lungekreft
We will identify plasma proteomics biomarkers for early diagnosis of lung cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients and controls. Artificial intelligent (AI) assisted proteomics classifier will be developed for early diagnosis of lung cancer.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
China
-
Hangzhou, China, Kina, 310009
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Study group: Patients with suspected or confirmed diagnosis of lung cancer. Control group: Non-cancer subjects including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
Beskrivelse
Inclusion Criteria:
- CT screening results showed that the size of pulmonary nodules was more than 5mm
- No treatment related to pulmonary nodules/lung cancer (including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy, etc.)
- Complete clinical and imaging data
- Chest CT/ low-dose spiral CT reports can be provided in the last 3 months
- Voluntarily sign informed consent
Exclusion Criteria:
- There is a history of tumor
- Clinically uncontrolled active infections, such as acute pneumonia, tuberculosis, etc.
- Received any treatment related to pulmonary nodules, such as antibiotics and hormones, in the past 4 weeks
- Complicated with other tumors and serious diseases of the heart, liver, kidney, brain, blood and other systems
- Participated in other clinical trials within the last 3 months
- Combined with liver and kidney insufficiency, hypoproteinemia and other diseases affecting protein content
- You are pregnant or breastfeeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Lung cancer group
Patients age over 18, with confirmed diagnosis of lung cancer. |
Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients . Plasma samples of control subjects were collected. |
|
Control group
Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc. |
Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients . Plasma samples of control subjects were collected. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma proteomic biomarkers
Tidsramme: 1 month after surgery
|
Plasma proteomic biomarkers for detection of lung cancer |
1 month after surgery
|
|
Model or classifier performance
Tidsramme: 1 month after surgery
|
Artificial intelligent (AI) assisted proteomics classifier will be developed for early diagnosis of lung cancer; and model or classifier performance including AUC, sensitivity, specificity, and accuracy |
1 month after surgery
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Weilin Wang, 2nd Affiliated Hospital, School of Medicine, Zhejiang University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2022-1109
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .